Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02097524 · ClinicalTrials.gov registry record · Phase 1
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT02097524 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT02097524, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
The main purposes of this study are to describe the pharmacodynamic effects, safety and pharmacokinetics of a single dose of sarilumab.
Interventions
- DRUG Tocilizumab
- DRUG Sarilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02097524
The ClinicalTrials.gov registry entry for NCT02097524 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tocilizumab is the first listed.
NCT02097524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02097524 about?
NCT02097524 is a clinical study titled "Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)". The main purposes of this study are to describe the pharmacodynamic effects, safety and pharmacokinetics of a single dose of sarilumab.
What is the current status of trial NCT02097524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2014-03. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02097524?
The interventions under investigation include: Tocilizumab (DRUG), Sarilumab (DRUG).
Who is sponsoring clinical trial NCT02097524?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.